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Objectives. We investigated the influence of lipoprotein(a)
[Lp(a)] serum levels on different endothelium-dependent vasodi-
lator stimuli representing different mechanisms of endothelium-
dependent vasodilation.
Background. Lp(a) is an independent predictor for the devel-
opment and progression of coronary artery disease. Impairment
of endothelium-dependent vasodilation of epicardial arteries has
been shown in patients with high levels of Lp(a).
Methods. In 108 patients with angiographically normal or
minimally diseased coronary vessels, vasomotor responses to
acetylcholine, cold pressor testing, increased blood flow and
nitroglycerin were assessed.
Results. Lp(a) levels >230 mg/dl were associated with significant
dose-dependent enhancement of the vasoconstrictor response to
acetylcholine [receptor-mediated vasodilation, p 5 0.002; acetyl-
choline 1026 mol/liter, 229 6 21% vasoconstriction with Lp(a)
levels >230 mg/dl vs. 25.6 6 25% with Lp(a) levels <30 mg/dl]. In
addition, vasoconstrictor response to cold pressor test (receptor-
and flow-mediated vasodilation) was significantly enhanced in
patients with Lp(a) levels >230 mg/dl (213 6 12% vs. 1.2 6 16%,
p 5 0.005). In contrast, strictly endothelium-dependent, but
non-receptor–mediated, flow-dependent dilation and endothelium-
independent dilation with nitroglycerin were not compromised.
Linear regression analysis revealed an inverse relation between
Lp(a) and both acetylcholine-induced (r 5 20.34, p 5 0.0007) and
cold pressor test–induced (r 5 20.44, p 5 0.0001) vasodilation.
By multivariate analysis, Lp(a) was a strong and independent
predictor of paradoxic vasoconstriction only in response to ace-
tylcholine and cold pressor testing. Impairment of coronary blood
flow increase in patients with Lp(a) levels >230 mg/dl did not reach
statistical significance.
Conclusions. High Lp(a) levels are associated with a selective
impairment of vasodilator capacity of receptor-mediated endothe-
lial stimuli. Impaired dilator capacity of the coronary circulation
associated with elevated Lp(a) levels may contribute to the
pathogenesis of myocardial ischemia in response to trigger mech-
anisms involving receptor-mediated stimulation such as sympa-
thetic activation.
(J Am Coll Cardiol 1997;30:927–34)
©1997 by the American College of Cardiology
Lipoprotein(a) [Lp(a)], first described by Berg (1) in 1963, has
been shown (2) to be an independent risk factor for athero-
sclerotic cardiovascular disease. However, the epidemiologic
studies are in conflict with respect to the importance of Lp(a)
as a risk factor for myocardial infarction (3). Lp(a) consists of
apoB100, the protein moiety of low density lipoprotein, linked
to apolipoprotein (a), which has an ;80% homology with
plasminogen (4). The size and concentration of Lp(a) are
mainly determined genetically by a polymorphism of apo(a)
and are fairly constant throughout life (5). Although the
biologic role of Lp(a) is still unknown, it does not seem to be
mandatory for the mammalian organism, as it is not found in
new world monkeys (2). However, the structure of Lp(a)
suggests a bridging function between the lipid and the coagu-
lation system (6). Experimental studies (7) indicate that Lp(a)
interacts with endothelial cells by binding to the plasminogen
receptor, thereby altering the fibrinolytic system. In addition,
Lp(a) migrates through endothelial cells into the vessel wall, is
capable of binding to macrophages (8) and can be found in
atherosclerotic plaques (9). The endothelium is one of the
primary targets of risk factors for atherosclerosis. Disturbances
of endothelial integrity, which occur in the presence of risk
factors for coronary artery disease, may contribute to the
pathogenesis of myocardial ischemia (10) and may precede the
development of overt coronary artery disease (11,12). Because
endothelial dysfunction is an early feature of atherogenesis
(13–16), impaired endothelium-dependent coronary vasomo-
tor responses may represent an important marker of early
vascular damage imposed by risk factors for coronary artery
disease. Thus, hypercholesterolemia and, in particular, ele-
vated levels of low density lipoprotein (LDL) are associated
with a blunted endothelium-mediated vasodilator capacity of
epicardial arteries (15,17) and the coronary microcirculation
(18,19). Experimental evidence (20) and clinical findings in
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hypercholesterolemic children (21) suggest that Lp(a) might
importantly contribute to endothelial dysfunction.
In children with familial hypercholesterolemia, the extent of
impairment of endothelium-dependent dilation of the brachial
artery appears to be directly related to the concentration of
Lp(a) (21). Recently, an altered response to the endothelium-
dependent dilator acetylcholine was reported (22) in epicardial
arteries of Japanese adults with elevated Lp(a) levels. To
assess whether impaired endothelium-dependent vasomotor
responses detected by pharmacologic testing with acetylcholine
extend to physiologically relevant stimuli, we studied endothe-
lial vasodilator function in response to increased blood flow
and sympathetic stimulation by cold pressor testing. In addi-
tion, we evaluated whether the effects of Lp(a) on endothelial
function are restricted to specific tests assessing endothelium-
mediated vasomotor responses, pointing toward the mecha-
nism whereby Lp(a) might interact with endothelial dysfunc-
tion. Because LDLs, which share the apoB100 with Lp(a),
mainly interact with receptor-mediated endothelium-dependent
vasodilator functions (23), we want to compare the effect of
Lp(a) on endothelial vasodilator function with other variables
of the lipid status.
Methods
Study patients. We studied 108 patients undergoing rou-
tine diagnostic cardiac catheterization. Patients with unstable
angina, recent myocardial infarction, valvular heart disease,
clinical evidence of heart failure or left ventricular hypertrophy
were excluded. Hypertension was defined as a .2-year history
of hypertension that required the initiation of antihypertensive
therapy by the primary physician. Hypercholesterolemia was
defined as fasting total serum cholesterol values exceeding the
75th percentile adjusted for age and gender. Smoking was
defined as at least 2 pack-years of cigarette smoking immedi-
ately before the study. However, all smokers refrained from
smoking $4 h before examination. Extent of disease was
defined as normal (smooth vessels in the entire coronary tree),
minimal disease (lumen irregularities ,30% focal stenosis) or
coronary artery disease (significant stenosis .50% in a vessel
other than the left anterior descending artery, the vessel under
study). Written informed consent was obtained from all pa-
tients before the study. The study protocol had been approved
by the ethical committee of the University of Freiburg. The
epicardial artery vasomotor responses of 38 of these patients
(12) and the vasomotor responses of the coronary microcircu-
lation of 62 of these patients (19) were reported previously.
Because of differences in protocol, not all three tests of
endothelium-dependent vasodilator function were performed
in every patient.
Study design. Vasoactive therapy, including administration
of calcium channel blocking agents, angiotensin-converting
enzyme inhibitors and long-acting nitrates, was discontinued
$24 h before cardiac catheterization. Beta-blockers were
discontinued $48 h before the catheterization. No patient was
receiving niacin medication. Diagnostic coronary angiography
was performed by a standard percutaneous femoral approach
with use of the Judkins technique. To assess coronary blood
flow variables, a 3F monorail Doppler catheter (Schneider,
Zu¨rich) with a 20-MHz pulsed Doppler crystal was advanced
into the left anterior descending coronary artery by a 0.014-in.
(0.036-cm) guide wire, or a 0.014 Doppler wire (Cardiomet-
rics) was used. The study protocol has been previously de-
scribed (12). In brief, sympathetic activation by cold pressor
testing was performed by immersion of the patient’s hand in
ice water for 90 s; flow-dependent dilation was assessed by
infusion of papaverine (7 mg) into the midportion of the left
anterior descending artery and measurement of a proximal
vessel segment, exposed to increased flow, but not to papav-
erine, 90 s after papaverine infusion; strictly receptor-mediated
dilation was analyzed by infusion of increasing dosages of the
endothelium-dependent vasodilator acetylcholine (1028 to
1026 mol/liter) into the left anterior descending artery. Nitro-
glycerin (0.2 to 0.3 mg) was injected into the ostium of the left
main stem to assess the maximal endothelium-independent
dilator capacity. Throughout the study, phasic and mean
intracoronary blood flow velocities, heart rate and aortic
pressure were continuously measured.
Quantitative coronary angiography. Coronary angiogra-
phy was performed with simultaneous biplane, multidirectional
and isocentric X-ray systems as previously reported (12,24),
and videodigitized end-diastolic frames were analyzed by au-
tomatic contour detection technique (25). A 6- to 8-mm
segment of the proximal left anterior descending artery distal
to the tip of the Doppler catheter was measured, and a mean
diameter for every segment was calculated for assessment of
vasomotor responses. Whenever possible, measurements were
obtained in both views of the biplane images, and cross-
sectional area was calculated from both views assuming an
elliptic shape. Only single-plane analysis was performed for
those coronary segments demonstrating overlapping with other
parts of the coronary tree in one view; in those cases, vessel
cross-sectional area was calculated by assuming a circular
shape.
To estimate directional changes in coronary blood flow, a
coronary flow index was calculated by multiplying the mean
Doppler-derived blood flow velocity, obtained immediately
before contrast injection, with the computed cross-sectional
area of the vessel segment distal to the tip of the Doppler
catheter. Coronary flow index was calculated only if the most
constricting epicardial coronary artery segment did not exceed
50% area reduction.
Abbreviations and Acronyms
apo 5 apolipoprotein
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
Lp(a) 5 lipoprotein(a)
NO 5 nitric oxide
TGF-beta 5 transforming growth factor-beta
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Lp(a) measurement. Lp(a) was measured with an ELISA
method by using polyclonal antibodies against apo(a) (Immu-
nozym, IMMUNO, Heidelberg). Lp(a) levels ,30 mg/dl were
considered to be within the normal range (26).
Statistical analysis. All data are expressed as mean
value 6 SD, if not stated otherwise. Statistical comparisons
were made by one-way analysis of variance (ANOVA). Dose-
response curves were assessed by a general linear model
(repeated measures, Scheffe´ post hoc multiple comparisons).
Linear regression analysis and nonparametric bivariate corre-
lation (Spearman rank correlation coefficient [rs]) were used to
compare vasomotor responses with Lp(a) values. For each
vasomotor test (maximal acetylcholine-induced epicardial va-
soreactivity, cold pressor test, flow-dependent dilation and
maximal acetylcholine-induced blood flow increase), a multi-
variate analysis using multiple stepwise linear regression tech-
niques was performed to examine potential interactions among
lipid components entering the following variables: serum LDL
cholesterol, serum high density lipoprotein (HDL) cholesterol
and Lp(a) values, which were log-transformed to a normal
distribution before the multivariate analysis was performed. A
forward entry stepping algorithm was used with the entry
criteria probability of F (0.05). Statistical significance was
assumed if the null hypothesis could be rejected at the p 5 0.05
level. All statistical analysis was performed by using SPSS for
Windows 7.0 (SPSS Inc.).
Results
The characteristics of the 108 patients are summarized in
Table 1. The distribution of serum Lp(a) levels (mg/dl) was
skewed toward lower concentrations (median 11; range 0.1 to
91; 25th percentile 1.3; 75th percentile 33; mean 22 6 25).
Lp(a) level was $30 mg/dl in 31 patients and ,30 mg/dl in 77;
the value of other lipid components in these two subgroups did
not differ significantly (total cholesterol 249 6 38 vs. 244 6 51
mg/dl, p 5 0.60; LDL cholesterol 165 6 33 vs. 171 6 44 mg/dl,
p 5 0.54; HDL cholesterol: 58 6 23 vs. 55 6 18 mg/dl, p 5
0.68).
By linear regression analysis and bivariate correlation, the
serum level of Lp(a) was not related to any other risk factor for
coronary artery disease, such as age, gender, smoking habits,
hypertension, total serum cholesterol, LDL cholesterol or
HDL cholesterol. However, Lp(a) levels were significantly
higher in patients with evidence of atherosclerotic epicardial
lumen irregularities than in patients with smooth coronary
arteries (26 6 27 [n 5 66] vs. 14 6 20 mg/dl [n 5 42], p 5
0.015).
Epicardial vasomotor responses. Acetylcholine was in-
fused in 96 patients. The maximal epicardial lumen area
change in response to acetylcholine in these patients was
212 6 26%. There was a direct inverse relation between the
level of Lp(a) and the maximal vasomotor response to acetyl-
choline (Fig. 1A), such that higher levels of Lp(a) were
associated with a significantly enhanced vasoconstrictor re-
sponse to acetylcholine. The correlation was also significant in
the bivariate analysis (rs 5 20.35, p 5 0.002) and tended to be
stronger for segments from patients with evidence of coronary
atherosclerotic disease (rs 5 20.27, p 5 0.041) than for
segments of patients with smooth coronary arteries (rs 5
20.30, p 5 0.057).
Acetylcholine elicited a dose-dependent increase in vaso-
constrictor responses (Fig. 2), with a significantly enhanced
vasoconstriction in response to acetylcholine in patients with
Lp(a) levels $30 mg/dl (n 5 27). The effect of enhanced
vasoconstriction in patients with elevated Lp(a) levels was seen
at all dosages of acetylcholine; however, the differences in-
creased in a dose-dependent manner.
Similarly, in the 71 patients who underwent cold pressor
testing, a significant inverse relation between cold pressor
test–induced epicardial vasomotor response and Lp(a) was
observed (Fig. 1B). Patients with Lp(a) levels $30 mg/dl
demonstrated significantly greater vasoconstriction in response
to sympathetic stimulation (213 6 12%, n 5 22) than did
patients with normal Lp(a) levels (11.2 6 15.5%, n 5 49, p 5
0.005) (Fig. 2). There was a significant inverse relation between
vasomotor responses to the cold pressure test and Lp(a) for all
segments on linear regression analysis (Fig. 1B) as well as
bivariate analysis (rs 5 20.38, p 5 0.001). However, no
significant relation was observed when segments of patients
with coronary atherosclerotic disease (rs 5 20.27, p 5 0.085)
and of patients without angiographic evidence of coronary
artery disease (rs 5 20.36, p 5 0.057) were analyzed sepa-
rately.
Lp(a) had no influence on non-receptor–mediated, flow-
dependent dilation (assessed in 78 patients; 115 6 11%
increase in lumen area). Flow-dependent dilation did not differ
between patients with Lp(a) levels $30 (13 6 9%, n 5 23) or
,30 mg/dl (16 6 11%, n 5 55, p 5 0.23) (Fig. 2). Linear
Table 1. Characteristics of the Study Patients
Age (yr) 56 6 9.3
Female/male 28/82 (24%/76%)
Extent of disease
Normal 42 (39%)
Minimal disease 42 (39%)
Coronary artery disease* 24 (22%)
Hypertension 60 (56%)
Smoker 30 (28%)
Pack-years 33 6 21
Family history of coronary artery disease 38 (35%)
Diabetes mellitus 10 (9.3%)
Lipid-lowering drug therapy 29 (27%)
Lipid status
Hypercholesterolemia† 63 (58%)
Serum cholesterol level (mg/dl) 245 6 47
Serum LDL level (mg/dl) 169 6 41
Serum HDL level (mg/dl) 56 6 20
Serum Lp(a) level (mg/dl) (median) 11
*Vessel other than left anterior descending coronary artery. †Total serum
cholesterol .75th percentile. Unless otherwise indicated, data presented are
mean value 6 SD or number (%) of patients. HDL 5 high density lipoprotein;
LDL 5 low density lipoprotein; Lp(a) 5 lipoprotein(a).
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regression (Fig. 1C) and bivariate analysis (rs 5 20.14, p 5
0.24) revealed no significant relation between flow-dependent
dilation and Lp(a) serum levels. In addition, when flow-
dependent dilation was normalized to maximal blood flow
response induced by papaverine, no significant relation be-
tween normalized flow-dependent dilation and Lp(a) could be
observed (rs 5 20.035, p 5 0.80). Normalized flow-dependent
dilation was not significantly different between patients with
Lp(a) levels ,30 (3.5 6 2.7%) or $30 mg/dl (3.9 6 2.9%, p 5
0.62).
The response to the endothelium-independent vasodilator
nitroglycerin was not related to Lp(a) levels on linear regres-
sion analysis (Fig. 2) or bivariate analysis (rs 5 20.13, p 5
0.21), as assessed in 93 patients with a mean vasodilation of
130 6 18% in response to nitroglycerin. However, there was a
significant inverse relation in patients with entirely smooth
coronary arteries (rs 5 20.34, p 5 0.037) compared with the
response of patients with evidence of coronary atherosclerotic
disease (rs 5 0.02, p 5 0.88). Nitroglycerin-induced dilation
did not differ between patients with Lp(a) levels $30 (28 6
17%, n 5 26) or ,30 mg/dl (31 6 18%, n 5 67, p 5 0.41) (Fig.
1D).
Multivariate analysis. In the multivariate analysis model
including LDL cholesterol, HDL cholesterol and log-
transformed Lp(a), Lp(a) independently determined the vaso-
motor response to acetylcholine and cold pressor testing
(Table 2). There was no influence of Lp(a) on non-receptor–
mediated flow-dependent dilation, which was independently
determined by LDL cholesterol. The influence of LDL on the
acetylcholine response did not reach statistical significance.
Because Lp(a) was related to the extent of coronary athero-
sclerotic disease, the latter variable was included in the multi-
variate analysis, which then continued to show a trend toward
Lp(a) determination of the maximal vasomotor response to
acetylcholine (p 5 0.076). The cold pressor test was related
only to Lp(a) (p 5 0.019) and the extent of disease (p 5 0.047).
In contrast, flow-dependent dilation was independently deter-
mined only by the extent of disease (p 5 0.020) and LDL
Figure 1. Relation between epicardial vasomotor responses and serum
Lp(a) levels (linear regression analysis). A, Maximal acetylcholine
(Achmax)-induced vasomotor response. B, Cold pressor testing. C,
Flow-dependent dilation. D, Nitroglycerin. Closed circles 5 evidence
of coronary atherosclerosis; open circles 5 smooth epicardial arteries.
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cholesterol (p 5 0.011) in these models. Similar models were
achieved when Lp(a) was entered without log transformation.
Microcirculation. Patients with Lp(a) serum levels $30
mg/dl demonstrated no significant difference in coronary blood
flow increase throughout all dosages of acetylcholine from that
of patients with normal Lp(a) levels (Fig. 3A; p 5 0.89 for 1028
mol/liter, p 5 0.50 for 1027 mol/liter and p 5 0.095 for 1026
mol/liter acetylcholine, respectively). In addition, after adjust-
ment for multiple measurements, the dose-response curves of
patients with Lp(a) levels $30 versus ,30 mg/dl were not
significantly different (p 5 0.26). For the entire study group,
there was no significant relation between maximal coronary
blood flow increase in response to acetylcholine infusion and
serum Lp(a) levels on linear regression analysis (Fig. 3B) and
bivariate analysis (rs 5 20.11, p 5 0.35).
In addition, by multivariate analysis, none of the entered
variables, including Lp(a), independently predicted the coro-
nary blood flow response to infusion of acetylcholine (Table 2).
No difference was observed in maximally achievable coronary
blood flow increases with papaverine in segments of patients
with Lp(a) levels .30 mg/dl (370 6 120%) compared to
segments of patients with Lp(a) levels ,30 mg/dl (390 6 150%,
p 5 0.77). Also, in bivariate analysis, no relation was observed
between Lp(a) levels and papaverine-induced blood flow
responses (rs 5 20.57, p 5 0.66). Normalization of
acetylcholine-induced coronary blood flow increases to
papaverine-induced blood flow increases did not substantially
alter the statistics of bivariate and multivariate analysis.
Discussion
Lp(a) has been shown (27–29) to be a predictor of coronary
artery disease, independent of cholesterol levels or other risk
factors. Evidence that Lp(a) is related to endothelial dysfunc-
tion in the human coronary circulation before the development
of overt atherosclerosis was recently reported (22) in a Japa-
nese population, in a study using a pharmacologic test with
acetylcholine to determine endothelial dysfunction. The
present study not only confirms these observations in a Cau-
casian population, but—more important—extends the role of
Lp(a) for endothelium-dependent vasodilation to the physio-
logically relevant stimulus of sympathetic activation and points
toward a potential underlying mechanism, namely, the specific
impairment of receptor-mediated vasodilation.
Receptor– and non-receptor–mediated pathways of endo-
thelium-dependent vasodilation might be differentially im-
Figure 2. Epicardial vasomotor responses for Lp(a)
levels ,30 (open bars) and $30 mg/dl (solid bars).
CPT 5 cold pressor testing; FDD 5 flow-dependent
dilation; NTG 5 nitroglycerin.
Table 2. Multivariate Analysis Including Lipid Variables
Acetylcholinemax-Induced
Epicardial Vasoreactivity Cold Pressor Test Flow-Dependent Dilation
Acetylcholinemax-Induced
Blood Flow Increase
Standardized
Coefficient p Value
Standardized
Coefficient p Value
Standardized
Coefficient p Value
Standardized
Coefficient p Value
Serum LDL cholesterol 20.19 0.092 20.078 0.57 20.36 0.007 20.23 0.10
Serum HDL cholesterol 0.050 0.67 0.010 0.94 0.045 0.73 0.069 0.62
Lp(a) (log-transformed) 20.28 0.018 20.46 0.001 20.16 0.22 20.030 0.82
Adjusted R2 0.066 0.15 0.090 0.004
Significance (ANOVA) 0.053 0.015 0.046 0.44
p values in italics indicate a statistically significant difference. Acetylcholinemax 5 maximal acetylcholine; ANOVA 5 analysis of variance; other abbreviations as
in Table 1.
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paired, depending on the risk factors for coronary artery
disease that are involved. Thus, strict attention must be paid to
the stimulus used to assess coronary endothelial vasodilator
function in order to evaluate the mechanisms by which risk
factors for coronary artery disease effect vasodilator function.
Our present results demonstrate that elevated Lp(a) levels are
associated with impaired endothelium-dependent epicardial
vasodilator function as assessed by intracoronary infusion of
acetylcholine or cold pressor testing. With both tests,
endothelium-dependent vasodilation is mediated by recep-
tors—particularly muscarinic receptors, in case of stimulation
with acetylcholine (30), and alpha-adrenergic receptors (31)
together with an increase in blood flow, in the case of
sympathetic activation induced by cold pressor testing. Cat-
echolamines, induced by cold pressor testing as well as acetyl-
choline, directly vasoconstrict vascular smooth muscle cells. It
is difficult to differentiate both (vasoconstricting and vasodilat-
ing) components; however, the differentiation is not relevant
physiologically, because the balance between the different
effects is of importance. Thus, the cold pressor test is a
physiologically relevant integrated measure of the effects on
endothelial and smooth muscle cells. In contrast to acetylcholine–
or cold pressor test–induced catecholamines, another physio-
logically relevant endothelial stimulus of epicardial vasodila-
tion—namely flow-dependent dilation—exerts its effects in a
purely endothelium-dependent manner. In addition, in con-
trast to acetylcholine or the cold pressor test, flow-dependent
dilation is mediated by way of a non-receptor–mediated path-
way (32). Increased shear stress appears to activate endothelial
potassium channels and to induce calcium influx and subse-
quent vasorelaxation (33). In addition, a kininergic, non-
receptor–mediated mechanism seems to be involved (34) in a
flow-dependent dilation. Lp(a) did not show any effect on
flow-dependent dilation, which indicates that Lp(a) selectively
interferes with the receptor-mediated bioavailability of nitric
oxide (NO), the endothelium-derived relaxing factor.
Mechanisms of Lp(a) effects on the vasculature. From
structural considerations, the hybrid nature of Lp(a), consist-
ing of apolipoprotein B (apoB) from the lipid system and
apo(a) with its homology to plasminogen from the fibrinolytic
system, offers some explanations for its action on the vascula-
ture. Lp(a) prolongs fibrinolysis by inhibiting plasmin genera-
tion, competing with plasmin on the endothelial cell surface
and activating plasminogen activator inhibitor (2,35). As plas-
min activates transforming growth factor-beta (TGF-beta),
which is proposed as a key inhibitor of atherogenesis (35),
Lp(a) might interact with the process of atherosclerosis be-
cause of its action on the fibrinolytic system. TGF-beta has
recently been shown (36) to be a potent stimulator of NO
synthase gene expression. However, the influence of these
mechanisms on endothelial function has not yet been estab-
lished.
More likely, Lp(a) effects are similar to the effects of LDL
cholesterol. Hypercholesterolemia has been shown to impair
endothelium-dependent vasodilation by inactivating NO as a
result of increased superoxide anion production (37) as well as
by interfering with the receptor-mediated pathways of the NO
synthase stimulation on the G-protein level. Lysophasphatidyl-
choline, a product of oxidative modification of LDL, selectively
inhibits pertussis toxin–sensitive Gi-2-protein, which mediates
receptor stimulation due to acetylcholine or catecholamines
(38). Like LDL, but using another mechanism, Lp(a) trans-
verses the endothelium and accumulates in the intima of
atherosclerotic arterial vessels and vein grafts (7,9,39). Exper-
imental studies suggest that owing to the more hydrophilic
apo(a) component, Lp(a) has a greater affinity to bind to
structures present in the vessel wall and probably greater
permeability than that of LDL, and it thus accumulates to a
relatively large amount in the vessel wall (26,40). In vitro,
Lp(a) binds avidly to macrophages and, after oxidative modi-
fication, is internalized by these cells (8,41). Experimental
evidence suggests that oxidized Lp(a), but not native Lp(a), is
a potent inhibitor of endothelium-dependent vasodilator func-
tion, even exceeding the effects of oxidized LDL (20).
Thus, similar to the mechanism of action of LDL choles-
terol, accumulation and oxidative modification of Lp(a) in the
vessel wall, might cause an increased oxidative stress in the
arterial wall, leading to subsequent reduction of bioavailability
of NO. It remains to be determined whether specific modifi-
Figure 3. A, Response of the microcirculation to acetylcholine for
Lp(a) levels ,30 and $30 mg/dl. B, Relation between maximal
coronary blood flow increase after infusion of acetylcholine (Achmax)
and serum Lp(a) levels. Solid circles 5 evidence of coronary athero-
sclerosis; open circles 5 smooth epicardial arteries.
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cation products of Lp(a) directly interact with the signal
transduction mechanism of receptor-mediated stimuli, compa-
rable or identical to those shown for LDL-derived lysophos-
phatidylcholine.
On multivariate analysis, the effects of Lp(a) are indepen-
dent of other risk factors for coronary artery disease including
elevated LDL serum cholesterol. They are also independent of
the presence or absence of epicardial atherosclerotic lesions,
suggesting that Lp(a) may be pathogenetically important for
early vascular damage. Despite similar effects of Lp(a) and
LDL cholesterol on receptor-mediated endothelial vasodila-
tion, Lp(a) and LDL cholesterol exert different effects on
non-receptor–mediated flow-dependent dilation. Whereas
Lp(a) has no effect on flow-dependent dilation, LDL choles-
terol seems to abolish it. The latter finding appears to be
contradictory to our previous report (16) in a smaller group of
patients. Impaired flow-dependent dilation in the coronary
artery has been previously related (16,33,42) to hypertension,
smoking and the extent of coronary atherosclerosis. However,
flow-dependent dilation of the brachial artery has also been
shown (21) to be impaired in children with hypercholesterol-
emia.
Lp(a) did not significantly impair acetylcholine-induced
vasodilation of the coronary microvasculature. Because Lp(a)
is related to the extent of atherosclerosis in the epicardial
arteries, the lack of effect of Lp(a) in the microcirculation—
where no overt atheroma develops (43)—might suggest a link
between the effects of Lp(a) on endothelium-dependent vaso-
motor responses and the extent of atherosclerotic wall thick-
ening. However, we cannot exclude that a higher dose of
acetylcholine would have shown an effect of Lp(a) on the
coronary microcirculation. In addition, the correlation be-
tween Lp(a) and receptor-mediated vasodilation was only
slightly better in segments of patients with atherosclerosis than
in those of patients without angiographic evidence of athero-
sclerosis.
Limitations of the study. We chose to analyze only one
coronary artery segment per patient, but differences in vaso-
reactivity exist within the same vessel exposed to the same risk
factors. These differences might be related to the extent of
atherosclerosis. However, we did not perform intravascular
ultrasound studies to accurately quantitate the extent of ath-
erosclerotic wall thickening. Thus, we might also not have
detected underlying beginning atherosclerotic disease in pa-
tients classified as having angiographically normal coronary
arteries.
Conclusions. In summary, this study demonstrates that
Lp(a) selectively impairs endothelium-dependent coronary
vasomotor function by inhibiting receptor-mediated vasodila-
tor responses. Because endothelial dysfunction is an important
marker of early arterial damage, the impaired dilator capacity
of the coronary circulation associated with elevated Lp(a)
levels may indicate not only a pathogenetically important role
for Lp(a) in atherogenesis, but also its possible contribution to
the pathogenesis of myocardial ischemia in response to trigger
mechanisms involving receptor-mediated stimulation such as
sympathetic activation or platelet activation with subsequent
serotonin release.
References
1. Berg K. A new serum type system in man: the Lp system. Acta Pathol
Microbiol Scand 1963;59:369–82.
2. Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904–10.
3. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipopro-
tein(a) and the risk of myocardial infarction. JAMA 1993;270:2195–9.
4. Byrne CD, Lawn RM. Studies on the structure and function of the
apolipoprotein(a) gene. Clin Genet 1994;46:34–41.
5. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a)
glycoprotein phenotypes: inheritance and relation to Lp(a) lipoprotein
concentrations in plasma. J Clin Invest 1987;80:458–65.
6. Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new
tricks. Nature 1987;330:113–4.
7. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation
of endothelial cell surface fibrinolysis and its potential role in atherosclerosis.
Nature 1989;339:303–5.
8. Zioncheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM. Interaction of
recombinant apolipoprotein(a) and Lp(a) with macrophages. J Clin Invest
1991;87:767–71.
9. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U.
Detection and quantitation of lipoprotein(a) in the arterial wall of 107
coronary bypass patients. Arteriosclerosis 1989;9:579–92.
10. Zeiher AM, Krause T, Scha¨chinger V, Minners J, Moser E. Impaired
endothelium-dependent vasodilation of coronary resistance vessels is asso-
ciated with exercise-induced myocardial ischemia. Circulation 1995;91:2345–
52.
11. Meredith IT, Yeung AC, Weidinger FF, et al. Role of impaired
endothelium-dependent vasodilation in ischemic manifestations of coronary
artery disease. Circulation 1993;87 Suppl V:V-56–66.
12. Zeiher AM, Drexler H, Wollschla¨ger H, Just H. Modulation of coronary
vasomotor tone in humans: progressive endothelial dysfunction with differ-
ent early stages of coronary atherosclerosis. Circulation 1991;83:391–401.
13. Zeiher AM, Scha¨chinger V, Saurbier B, Just H. Assessment of endothelial
modulation of coronary vasomotor tone: insights into a fundamental func-
tional disturbance in vascular biology of atherosclerosis. Basic Res Cardiol
1994;89 Suppl 1:115–28.
14. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction
induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med
1986;315:1046–51.
15. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to
acetylcholine relates to risk factors for coronary artery disease. Circulation
1990;81:491–7.
16. Zeiher AM, Scha¨chinger V, Minners J. Long-term cigarette smoking impairs
endothelium-dependent coronary arterial vasodilator function. Circulation
1995;92:1094–100.
17. Zeiher AM, Scha¨chinger V, Hohnloser SH, Saurbier B, Just H. Coronary
atherosclerotic wall thickening and vascular reactivity in humans: elevated
high-density lipoprotein levels ameliorate abnormal vasoconstriction in early
atherosclerosis. Circulation 1994;89:2525–32.
18. Egashira K, Inou T, Hirooka Y, et al. Impaired coronary blood flow response
to acetylcholine in patients with coronary risk factors and proximal athero-
sclerotic lesions. J Clin Invest 1993;91:29–37.
19. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary
blood flow modulation in humans: effects of age, atherosclerosis, hypercho-
lesterolemia, and hypertension. J Clin Invest 1993;92:652–62.
20. Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endothelium-
dependent dilation in rabbit arteries by oxidized lipoprotein(a): role of
oxygen-derived radicals. Circulation 1995;92:1582–9.
21. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge
DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early
event in children with familial hypercholesterolemia and is related to the
lipoprotein(a) level. J Clin Invest 1994;93:50–5.
22. Tsurumi Y, Nagashima H, Ichikawa KI, Sumiyoshi T, Hosoda S. Influence of
plasma lipoprotein(a) levels on coronary vasomotor response to acetylcho-
line. J Am Coll Cardiol 1995;26:1242–50.
23. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunc-
933JACC Vol. 30, No. 4 SCHA¨CHINGER ET AL.
October 1997:927–34 LP(a) AND CORONARY ENDOTHELIAL FUNCTION
tion: potential mechanisms underlying reduction in EDRF/nitric oxide
activity. Circulation 1992;85:1927–38.
24. Scha¨chinger V, Zeiher AM. Quantitative assessment of coronary vasoreac-
tivity in humans in vivo: importance of baseline vasomotor tone in athero-
sclerosis. Circulation 1995;2087–94.
25. Zeiher AM, Drexler H, Wollschla¨ger H, Saurbier B, Just H. Coronary
vasomotion in response to sympathetic stimulation in humans: importance of
the functional integrity of the endothelium. J Am Coll Cardiol 1989;14:1181–90.
26. Scanu A, Fless GM. Lipoprotein(a): heterogeneity and biological relevance.
J Clin Invest 1990;85:1709–15.
27. Dahle´n GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis
1995;108:111–26.
28. Armstrong VW, Cremer P, Eberle E, et al. The association between serum
Lp(a) concentrations and angiographically assessed coronary atherosclero-
sis: dependence on serum LDL levels. Atherosclerosis 1986;62:249–57.
29. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as a predictor of
myocardial infarction in comparison to fibrinogen, LDL cholesterol and
other risk factors: results from the prospective Go¨ttingen Risk Incidence and
Prevalence Study (GRIPS). Eur J Clin Invest 1994;24:444–53.
30. Bassenge E, Busse R. Endothelial modulation of coronary tone. Prog
Cardiovasc Dis 1988;30:349–80.
31. Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary
arteries by noradrenaline and serotonin. Nature 1983;305:627–30.
32. Ohno M, Gibbons GH, Dzau VJ, Cooke JP. Shear stress elevates endothelial
cGMP: role of potassium channel and G protein coupling. Circulation
1993;88:193–7.
33. Niebauer J, Cooke JP. Cardiovascular effects of exercise: role of endothelial
shear stress. J Am Coll Cardiol 1996;28:1652–60.
34. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in
human coronary vasomotor control. Circulation 1995;92:3424–30.
35. Grainger DJ, Kemp PR, Metcalfe JC, et al. The serum concentration of
active transforming growth factor-b is severely depressed in advanced
atherosclerosis. Nat Med 1995;1:74–9.
36. Inoue N, Venema RC, Sayegh HS, Ohara Y, Murphy TJ, Harrison DG.
Molecular regulation of the bovine endothelial cell nitric oxide synthase by
transforming growth factor-b1. Arterioscler Thromb Vasc Biol 1995;15:
1255–61.
37. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases
endothelial superoxide anion production. J Clin Invest 1993;91:2546–51.
38. Flavahan NA, Vanhoutte PM: Endothelial cell signaling and endothelial
dysfunction. Am J Hypertens 1995;8 Suppl:28S–41S.
39. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM.
Atherogenesis in transgenic mice expressing human apolipoprotein(a). Na-
ture 1992;360:670–2.
40. Nielsen LB, Nordestgaard BG, Stender S, Niendorf A, Kjeldsen K. Transfer
of lipoprotein(a) and LDL into aortic intima in normal and in cholesterol-
fed rabbits. Arterioscler Thromb Vasc Biol 1995;15:1492–502.
41. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde
modification of lipoprotein(a) produces avid uptake by human monocyte-
macrophages. J Biol Chem 1993;267:4143–51.
42. Cox DA, Vita JA, Treasuare CB, et al. Atherosclerosis impairs flow-
mediated dilation of coronary arteries in humans. Circulation 1989;80:458–
65.
43. Juergens JL, Bernatz PE. Atherosclerosis of the extremities. In: Juergens JL,
Spittell JA, Fairbairn JFI, editors. Peripheral Vascular Disease. Philadel-
phia: Saunders, 1980:253–93.
934 SCHA¨CHINGER ET AL. JACC Vol. 30, No. 4
LP(a) AND CORONARY ENDOTHELIAL FUNCTION October 1997:927–34
